Activist Investor Oramed Pharmaceuticals Increases Stake in Nano Dimension, Reiterates Dissatisfaction

summarizeSummary

Oramed Pharmaceuticals, an activist investor, has increased its stake in Nano Dimension to 5.2% through additional share purchases and reiterated its intent to engage with management regarding performance and governance.

check_boxKey Events

• Increased Stake

  Oramed Pharmaceuticals increased its beneficial ownership in Nano Dimension to 5.2% of outstanding shares.

• Additional Share Purchases

  Oramed acquired an additional 1,425,000 ordinary shares for approximately $2.8 million in open market transactions on February 17-18, 2026.

• Reiterated Activist Intent

  Oramed communicated its dissatisfaction with Nano Dimension's management and expressed intent to further engage on performance, strategic direction, shareholder value, and governance.

• Follows Poison Pill Adoption

  This filing follows Nano Dimension's adoption of a shareholder rights agreement (poison pill) on February 3, 2026, indicating continued pressure from the activist investor.

auto_awesomeAnalysis

This amended Schedule 13D reveals Oramed Pharmaceuticals' continued aggressive stance towards Nano Dimension. Following Nano Dimension's adoption of a poison pill, Oramed has not only increased its beneficial ownership to 5.2% through recent open market purchases totaling approximately $2.8 million but has also explicitly communicated its dissatisfaction with management and intent to further engage on strategic direction and governance. This signals a deepening activist battle, indicating Oramed is not deterred by the defensive measures and plans to continue pressing for changes. Investors should anticipate ongoing corporate governance discussions and potential proxy contests.